Status:
RECRUITING
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
University of California, San Francisco
Conditions:
Rheumatoid Arthritis
Interstitial Lung Disease
Eligibility:
All Genders
18-90 years
Brief Summary
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a grou...
Detailed Description
The central hypothesis is that novel quantitative imaging and specific blood markers will be associated with progressive RA-ILD. The hypothesis will be tested through collection and analysis of periph...
Eligibility Criteria
Inclusion
- Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria
- 18 years of age or older
Exclusion
- Prior medication treatment specifically for RA-ILD
- Inability to give informed consent
- Pregnant women
Key Trial Info
Start Date :
January 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2034
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06397677
Start Date
January 22 2024
End Date
January 1 2034
Last Update
May 3 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143
2
University of Colorado Denver
Aurora, Colorado, United States, 80045
3
University of Kansas
Kansas City, Kansas, United States, 66103
4
University of Michigan
Ann Arbor, Michigan, United States, 48109